[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Standard
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. / Siebels, M; Hegele, A; Varga, Z; Oberneder, R; Doehn, C; Heinzer, Hans; Deutsche, Gesellschaft Für Immun- Und Targeted Therapie E.V.
In: UROLOGE, Vol. 50, No. 9, 9, 2011, p. 1110-1117.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
AU - Siebels, M
AU - Hegele, A
AU - Varga, Z
AU - Oberneder, R
AU - Doehn, C
AU - Heinzer, Hans
AU - Deutsche, Gesellschaft Für Immun- Und Targeted Therapie E.V.
PY - 2011
Y1 - 2011
N2 - Since 2006 in Germany six different target drugs for therapy in metastatic renal cell cancer (mRCC) have been used. Comparative studies for the application with the same indication are absent, and the order of potential sequential therapy is up to now unclear. The aim of the study was to collect data on therapy decisions in Germany regarding mRCC in the age of "targeted therapy". At the same time the study addressed the central question of sequencing of the different therapy options. In addition, the data of this study were to be compared to a study already published in 2008.
AB - Since 2006 in Germany six different target drugs for therapy in metastatic renal cell cancer (mRCC) have been used. Comparative studies for the application with the same indication are absent, and the order of potential sequential therapy is up to now unclear. The aim of the study was to collect data on therapy decisions in Germany regarding mRCC in the age of "targeted therapy". At the same time the study addressed the central question of sequencing of the different therapy options. In addition, the data of this study were to be compared to a study already published in 2008.
KW - Adult
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Disease Progression
KW - Physician's Practice Patterns
KW - Protein-Tyrosine Kinases/antagonists & inhibitors
KW - Data Collection
KW - Antineoplastic Agents/administration & dosage/adverse effects
KW - Benzenesulfonates/administration & dosage/adverse effects
KW - Carcinoma, Renal Cell/drug therapy/pathology
KW - Drug Delivery Systems
KW - Indoles/administration & dosage/adverse effects
KW - Kidney Neoplasms/drug therapy/pathology
KW - Pyridines/administration & dosage/adverse effects
KW - Pyrroles/administration & dosage/adverse effects
KW - Sirolimus/administration & dosage/adverse effects/analogs & derivatives
KW - TOR Serine-Threonine Kinases/antagonists & inhibitors
KW - Adult
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Disease Progression
KW - Physician's Practice Patterns
KW - Protein-Tyrosine Kinases/antagonists & inhibitors
KW - Data Collection
KW - Antineoplastic Agents/administration & dosage/adverse effects
KW - Benzenesulfonates/administration & dosage/adverse effects
KW - Carcinoma, Renal Cell/drug therapy/pathology
KW - Drug Delivery Systems
KW - Indoles/administration & dosage/adverse effects
KW - Kidney Neoplasms/drug therapy/pathology
KW - Pyridines/administration & dosage/adverse effects
KW - Pyrroles/administration & dosage/adverse effects
KW - Sirolimus/administration & dosage/adverse effects/analogs & derivatives
KW - TOR Serine-Threonine Kinases/antagonists & inhibitors
M3 - SCORING: Zeitschriftenaufsatz
VL - 50
SP - 1110
EP - 1117
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 9
M1 - 9
ER -
